The CEO Olympus Fired for Asking Where the Money Went

Michael Woodford was 51 years old in October 2011. He had joined Olympus in 1981 at the bottom of the British subsidiary, selling medical scopes to hospitals in the north of England, and had spent the entire three decades since at the company. He had become managing director of Olympus Europe in 2005 and chief operating officer of the parent company in April 2011. On October 1, 2011, after a brief handover, he was promoted to president and chief executive officer.

The board's reasoning, as Woodford was told it at the time, was straightforward. Olympus was losing share in its core endoscopy and digital camera markets. Sony and Canon had eaten the camera business. Medical device competitors were gaining ground in Europe and the United States. The board, led by chairman Tsuyoshi Kikukawa, wanted an outsider's perspective on cost-cutting and global expansion. Woodford was English, multilingual, fluent in international markets, and — crucially — already understood how Olympus actually worked from the inside. He had thirty years of company knowledge that an external hire would never have.

What the board did not tell Woodford, and what he would only piece together later, was that the previous chairman Toshiro Shimoyama and the current chairman Kikukawa had spent fifteen years presiding over an internal accounting scheme so old that most of the executives who had originally constructed it were now retired or dead. The scheme needed maintenance. It needed someone to keep approving the unwinding transactions. What it did not need was a CEO who would read the M&A files.

Woodford's first week as CEO was supposed to be ceremonial. He toured the headquarters, met with division heads, and was briefed on the strategic plan. On day five he asked for the post-mortem files on the four largest acquisitions Olympus had made in the previous decade. He had a specific reason. The market commentary on Olympus during 2011 had repeatedly flagged that its goodwill writedowns were unusually large — the company had paid premium prices for assets that were now being amortised against earnings every quarter. Woodford wanted to understand what had been bought, what had been promised, and what had actually arrived.

The biggest single deal was Olympus's 2008 acquisition of Gyrus Group, a London-listed maker of surgical and medical devices. The headline price was $2.2 billion. That was approximately twice the consensus broker valuation of Gyrus at the time. The strategic rationale, on paper, was that Gyrus would expand Olympus's product line in minimally invasive surgery — a complement to its endoscopy franchise. In practice, Olympus had paid roughly twelve times Gyrus's annual revenue, more than three times its book value, and had subsequently written down a substantial portion of the goodwill from the deal.

Three other acquisitions sat in the file alongside Gyrus. In 2006 and 2007 Olympus had paid a combined ¥73.5 billion (about $773 million at the time) for three small Tokyo-based companies. The first made microwave cookware. The second was a small recycling and waste-management firm. The third sold cosmetic skincare products. None of the three companies were in markets Olympus operated in. None had revenue lines greater than $50 million per year. By the time Woodford pulled the file in October 2011, all three had been written down to a combined book value of roughly $200 million. Most of the original purchase price had been amortised away as goodwill impairments — quietly, quarter by quarter, with no public discussion of why Olympus had bought them in the first place.

Buried in the third box of the Gyrus file was a document titled 'Advisor Fee Schedule, Project Genesis'. Olympus had retained a financial advisor on the Gyrus transaction — a small entity called AXAM Investments, registered in the Cayman Islands, with no listed phone number, no listed staff, and no public record of any prior or subsequent transactions. AXAM had been paid an initial fee of $20 million on signing. AXAM had then been paid additional fees, structured as performance bonuses tied to Olympus's stock price post-deal, that brought the total to $687 million by the time the engagement closed in 2010.

Woodford had spent his career around medical-device acquisitions. He knew what a normal advisory fee looked like. On a $2.2 billion deal in 2008, the major Wall Street and London banks — Morgan Stanley, Goldman Sachs, Lazard — would have charged in the range of 0.5 to 1.5 percent. Even a small specialist boutique would have charged maybe 2 percent at most. AXAM had taken 31 percent. The fee was, by an order of magnitude, larger than any M&A advisory fee Woodford had seen in three decades in the industry.

It was also larger than every other advisory fee Olympus had ever paid combined. It was approximately one-third of Olympus's market capitalization at the time the deal closed. It was more, in dollar terms, than the entire net income Olympus had generated across its medical-devices division in the three years leading up to the transaction. And it had been signed off by the chairman, Tsuyoshi Kikukawa, with no board minutes recording any discussion of the size of the fee or the identity of AXAM Investments.

Woodford spent his second weekend in Tokyo working through the file with a single calculator and the disclosed Olympus financial statements. By the morning of his eleventh day in office, he had reached a conclusion: either the AXAM payment was the largest and most poorly structured advisory fee in modern corporate history, or it was not actually an advisory fee.

On October 11, 2011, Woodford circulated a six-page memorandum to chairman Kikukawa, with copies to the head of internal audit, to PricewaterhouseCoopers (Olympus's auditor), and to the chair of the company's audit committee. The memo asked, in formal corporate English translated into Japanese, for written explanations of: the strategic rationale for the three Tokyo small-cap acquisitions; the basis on which the Gyrus advisory fee to AXAM had been negotiated and approved; the corporate identity of AXAM Investments and the executives signing for it; and the accounting treatment used to amortise the resulting goodwill into Olympus's published earnings.

Kikukawa's reply came back two days later. It was three sentences long. It said, in summary, that the questions were causing disturbances within the senior management team and were inconsistent with the consensus-driven decision-making style of the company. It did not address any of the specific questions. It did not provide any of the requested documents.

Woodford sent a second memo the next morning, reiterating the questions and adding a paragraph noting that he was, as chief executive officer, legally obliged under both Japanese law and the listing rules of the London and Tokyo Stock Exchanges to investigate any irregularities he became aware of. He asked specifically that the audit committee retain an external forensic accounting firm — he suggested Deloitte's UK forensic practice — to review the AXAM payments.

Three days later, the board summoned Woodford to the meeting that ended his career at Olympus. The vote was unanimous. The press release that went out that afternoon described the dismissal as a result of 'cultural differences' and made no reference to the questions Woodford had been asking.

Woodford had reasons to be afraid. Japanese corporate scandals had a long and reported history of mysterious deaths — bankers found at the bottom of buildings, executives discovered in their cars in remote parking lots — when matters touched on Yakuza-adjacent commercial interests. He did not know, on the morning of October 15, 2011, whether AXAM had been a Yakuza-linked entity. He did know that someone had been willing to pay $687 million to keep the underlying transaction from being scrutinized, and that he had just become the only person in the world holding the documents who was no longer subject to Olympus's control.

From Heathrow he went directly to a hotel near the Financial Times offices, hired a private security firm to monitor his apartment for the next thirty days, and called Jonathan Soble, the FT's Tokyo correspondent, who had been tracking Olympus's odd accounting for months. Within twelve hours Soble and the FT's London-based corporate-investigations team had a copy of Woodford's full file. By the end of the week the file was also in the hands of Reuters, the Wall Street Journal, the New York Times, and three of the four major Tokyo dailies. Olympus's stock, which had closed at ¥2,482 on the day of Woodford's dismissal, opened on October 19 at ¥1,895 and continued to fall. By the start of November it was below ¥500. The market capitalization of the company had fallen by approximately 80 percent in three weeks.

The Tokyo Stock Exchange placed Olympus under supervisory monitoring. The Securities and Exchange Surveillance Commission opened a criminal investigation. The UK's Serious Fraud Office and the FBI both opened parallel reviews on the AXAM fee, given the Cayman Islands and US dollar dimensions of the transaction. Within ten days of Woodford going public, the Olympus board commissioned an independent investigation by a panel of three senior Japanese lawyers, led by former supreme court justice Tatsuo Kainaka. The Kainaka report, delivered in early December 2011, would describe the actual scheme that the AXAM payment had been hiding.

The Japanese term tobashi roughly translates as 'the fly-away.' In financial terms, it describes a practice that was widespread in Japan from the 1980s through the early 2000s: when a company had unrealised losses on financial investments, it would 'fly the losses away' by selling the impaired assets to a friendly third party at the original purchase price — typically a small affiliate, a special-purpose vehicle, or a foreign trust — and immediately agreeing to repurchase them later at the same price. The losses sat on the third party's books, off the company's published statements, until the company found a way to absorb them quietly.

Olympus had been running a tobashi scheme since the late 1980s. Like many large Japanese corporates of that era, it had used its strong cash flow to buy financial securities in the late-bubble years — Japanese equities, derivatives, and structured products — and had accumulated losses estimated at roughly ¥130 billion (about $1.7 billion at 2011 exchange rates) when those markets crashed in 1990 and 1991. Rather than write the losses off and report a multi-year loss to shareholders, three successive chairmen — Toshiro Shimoyama, Masatoshi Kishimoto, and finally Tsuyoshi Kikukawa — had authorized parking the impaired securities with a series of friendly third parties: small Tokyo-based investment companies, Cayman Islands SPVs, and at least one Hong Kong shell.

By the mid-2000s the scheme needed an exit. The third parties holding the losses were demanding to be made whole, and Japanese accounting standards were tightening in ways that would eventually require the parked losses to surface. Olympus's solution, designed by a small group of executives and outside advisors who included two former Nomura Securities salesmen later implicated in the case, was to engineer fake acquisitions. Olympus would buy a series of small Japanese companies for inflated prices — the cookware, recycling, and cosmetics firms — and would book the difference between the inflated price and the real value as 'goodwill.' The cash from the inflated portion of the purchase price would flow, through layers of intermediary entities, back to the third parties holding the parked losses. The losses would be quietly absorbed. The goodwill would be written down on Olympus's books over a series of quiet quarters.

The Gyrus deal was the largest single piece of the unwinding. The $687 million 'advisory fee' to AXAM had been the conduit for absorbing the remaining tobashi liabilities. AXAM was not an advisory firm. It was a settlement vehicle for what was, by 2011, the largest corporate accounting cleanup in Japanese history.

The Kainaka report identified seventeen executives — current and former — as having known about the scheme at various points. Three of them, including chairman Kikukawa, would receive suspended three-year prison sentences in 2013 for falsifying accounts. Olympus the corporation would be fined approximately $7 million by Japanese authorities and would face civil litigation that would drag on for another five years. Olympus the conspiracy was finished.

The most surprising part of the Olympus story is the part where the company survived. By the time the Kainaka report was published in December 2011, the market had largely concluded that Olympus was either going to file for bankruptcy or be broken up and sold to foreign acquirers. Sony and Canon were rumored as potential buyers of the medical-imaging business. Bain Capital and KKR were rumored as potential restructuring sponsors. None of those things happened. Sony eventually took a 5 percent strategic stake. The accounting was restated. New management was installed. The fraud, in dollar terms, was less than 5 percent of Olympus's then-current market value when the company traded around ¥2,500 per share. The medical scopes business — which is what the company actually did — kept selling medical scopes.

By mid-2017, Olympus's stock had recovered to ¥4,500 per share, well above its pre-scandal level. The medical-devices division, freed from having to subsidise an opaque accounting cleanup, posted record operating margins. By 2020 Olympus had divested its consumer camera business entirely (sold to a Japanese private equity firm) and refocused as a pure-play medical technology company. The market capitalization at the end of 2024 was approximately three times what it had been on the day Woodford was fired.

Michael Woodford, the man whose memo started all of this, never returned to Japanese corporate life. He sued Olympus for wrongful dismissal in the UK courts and reached a settlement in 2012 that paid him approximately $15 million. He wrote a book called Exposure that detailed the entire affair. He gave talks on corporate governance and whistleblower protection. He was offered, and declined, a seat on the new Olympus board after the cleanup. He has not, in the decade since, held another senior corporate position.

The lesson the Olympus case keeps offering to corporate-governance scholars is the asymmetry of the costs. The scheme had run for two decades. Three chairmen had approved it. Seventeen executives had known about it. The auditor had questioned it without escalating. The Tokyo Stock Exchange had not noticed it. The first person who actually triggered the cleanup was a CEO who had been in the role for fourteen days and asked a question in writing. The cost of asking the question was his job. The cost of not asking the question, accumulated across two decades and a global financial crisis, was the entire conspiracy. The cheaper path, in retrospect, was always the one Olympus made impossible to take.